Showing 4851-4860 of 5234 results for "".
DASIL and the ASDS
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/dasil-and-the-asds/19054/A new partnership between DASIL and the ASDS is intended to improve and expand education for dermatologists and cosmetic surgeons. Michael H. Gold, MD explains.In-Review: Two New Melanoma Agents Approved
https://practicaldermatology.com/topics/skin-cancer-photoprotection/in-review-two-new-melanoma-agents-approved/21534/Utilizing genetic abnormalities, new therapies are carving out new possibilities for melanoma treatment.New Frontiers in Neurotoxins
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/new-frontiers-in-neurotoxins/21638/Recent innovations offer patients greater variety and potentially better outcomes.Updating Approaches to Psoriasis
https://practicaldermatology.com/topics/psoriasis/evaluating-the-state-of-psoriasis-care/21660/Recent guidelines from the National Psoriasis Foundation point to new directions in research and therapy that will continue to shape psoriasis therapy.Support for Population- Based Skin Cancer Screenings
https://practicaldermatology.com/topics/skin-cancer-photoprotection/support-for-population--based-skin-cancer-screenings/21675/A new study offers data to show that general skin cancer screenings by dermatologists and properly trained physicians can reduce morbidity and mortality.Electronic Health Records
https://practicaldermatology.com/topics/practice-management/electronic-health-records/19383/Dr. Kaufmann discusses EHRs, government incentives, and the importance of choosing a system that is right for each practice. He offers tips for residents and young physicians for choosing and using electronic health records.Journal Club: Oral JAK Inhibitors in Moderate-to-Severe AD
https://practicaldermatology.com/programs/practical-dermatology/journal-club-oral-jak-inhibitors-moderate-severe-ad/24539/Peter Lio, MD, talks with Robert Sidbury, MD, MPH, a dermatologist at Seattle Children's Hospital, about nuanced differences in guideline-recommended use of oral JAK inhibitors in pediatric patients with moderate-to-severe atopic dermatitis (AD) provided in the Annals of Allergy, Asthma, and ImmunolMaking Connections: Success in Your First Five Years
https://practicaldermatology.com/topics/practice-management/webinar-making-connections-success-in-your-first-five-years/19819/Experts share practical guidance to help dermatologists chart a course for success. Topics range from getting involved in clinical trials to finding opportunities for leadership. Learn how to gain confidence prescribing systemic agents, and explore opportunities in medical dermatology.Diversity in the Dermatology Workforce: What Can We Do?
https://practicaldermatology.com/topics/practice-management/diversity-in-the-dermatology-workforce-what-can-we-do/23057/Medicine in general lacks workforce diversity. Dermatology fares worse than other specialties. Here’s a closer look at the problem.FDA Approves Axillary Hyperhidrosis Treatment; Study Examines Biologic Outcomes in Psoriasis
https://practicaldermatology.com/series/dermwire-tv/fda-approves-axillary-hyperhidrosis-treatment-study-examines-biologic-outcomes-psoriasis/26562/In this week's DermwireTV, the FDA approves a first-of-its-kind gel for axillary hyperhidrosis; a new analysis examines how smoking, BMI, and age affect biologic outcomes in psoriasis; and the CEO of Aerolase joins us to discuss the latest trends in the aesthetic laser market.